Biological Therapy in Treating Women With Breast Cancer That Has Spread to the Liver

DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed\* breast adenocarcinoma metastatic to the liver * Solitary or multiple hepatic metastases * No malignant involvement of \> 40% of the estimated liver volume NOTE: \*Must be from the hepatic tumor designated for study injection * Metastatic liver tumors must be measurable in ≥ 2 dimensions on CT scan or MRI * At least 1 metastatic hepatic tumor ≥ 2 cm in diameter must be visualized by ultrasound and accessible for percutaneous injection under ultrasound guidance * Extrahepatic metastasis allowed * No solitary hepatic metastasis eligible for liver resection * No clinical evidence for severe liver disease (e.g., prior or current ascites or portosystemic encephalopathy) * Hormone-receptor status not specified PATIENT CHARACTERISTICS: * Female * Menopausal status not specified * Granulocyte count ≥ 1,500/mm\^3 * Hemoglobin ≥ 9.0 g/dL * Platelet count ≥ 100,000/mm\^3 * PT ≤ 14.5 sec * Creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 45 mL/min * Bilirubin ≤ 2 times upper limit of normal (ULN) * Transaminases ≤ 2.5 times ULN * Karnofsky performance status ≥ 70% * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for at least 2 months after completion of study treatment * No active infection or serious intercurrent medical illness * No HIV infection * Life expectancy ≥ 16 weeks * No other malignancy within the past 5 years except inactive nonmelanoma skin cancer, in situ carcinoma of the cervix, or grade 1 papillary bladder cancer * At highest dose level, patient must weigh ≥ 30 kg PRIOR CONCURRENT THERAPY: * No systemic immunosuppressive drugs, including corticosteroids, within 2 months prior to study entry * Not require immunosuppressive drugs or anticoagulant therapy with heparin or warfarin for at least 2 months after study treatment * No chemotherapy within 4 weeks of study entry (6 weeks for nitrosoureas)